, /PRNewswire/ -- Allied Market Research has recently published a report, titled, According to the report, the global degenerative disc disease treatment market generated in 2022, and is anticipated to generate by 2032, rising at a CAGR of 5.5% from 2023 to 2032. The increasing prevalence of degenerative disc disease (DDD) among the aging population, growing awareness about spine health and available treatment options, and the innovations in imaging technology & surgical tools are the factors expected to drive the growth of the global degenerative disc disease treatment market in the forecast period from 2023 to 2032.
However, the increasing availability of various alternative treatment and pain management methods for degenerative disc disease may restrict market growth in the coming future. Contrarily, technological innovations in medical technology, such as robotics, 3D printing, and advanced imaging techniques is expected to offer remunerative opportunities for the degenerative disc disease treatment market expansion during the forecast period. The NSAIDs (non-steroid anti-inflammatory drugs) sub-segment accounted for the largest global degenerative disc disease treatment market share of 35.
1% in 2022 and is expected to hold major share and rise at a CAGR of 6.2% during the forecast period. NSAIDs' effectiveness in reducing pain, inflammation, and fever, their over-the-counter availability, and their ability to address multiple symptoms simultaneously drive their widesprea.
